Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 9Emgality

02 1Emgality/Rayvow

PharmaCompass

01

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

Brand Name : Emgality

arrow
ESCRS
Not Confirmed

Galcanezumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 363

2019 Revenue in Millions : 163

Growth (%) : 123

blank

02

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

03

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

04

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

05

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

06

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

07

Brand Name : Emgality/Rayvow

Galcanezumab, Lasmiditan

arrow
ESCRS
Not Confirmed

Brand Name : Emgality/Rayvow

arrow
ESCRS
Not Confirmed

Galcanezumab, Lasmiditan

Main Therapeutic Indication : Neurology

Currency : USD

2024 Revenue in Millions : 107

2023 Revenue in Millions : 0

Growth (%) : NA

blank

08

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

09

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

10

Brand Name : Emgality

Galcanezumab

arrow
ESCRS
Not Confirmed

Brand Name : Emgality

arrow
ESCRS
Not Confirmed

Galcanezumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 163

2018 Revenue in Millions : 5

Growth (%) : 3,216

blank